288. 自己免疫性後天性凝固因子欠乏症 Disease details / Clinical trials / Drug dev / DR info

Activated prothrombin complex concentrate
   Hoffmann-La Roche
      2025   -   NCT06883240   Belgium;Colombia;Italy;Japan;Spain;United Kingdom
Advate
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxalta Innovations GmbH
      -   Phase 3   EUCTR2016-001477-33-Outside-EU/EEA   Russian Federation;Turkey;Ukraine;United States
   Baxter Innovations GmbH
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
   St. James' Hospital
      2013   -   EUCTR2013-003240-23-IE   Ireland
   Takeda
      2024   Phase 3   NCT05582993   France;Ireland;Italy;Japan;United States
Advate 1000 IU
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2023   Phase 3   EUCTR2020-003304-13-IT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
   Takeda Development Center Americas, Inc.
      2024   Phase 3   EUCTR2020-003304-13-NL   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-NO   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-FR   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-ES   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-AT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-SE   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-IE   Austria;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
Advate 1000 IU powder and solvent FOR solution FOR injection
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   Baxalta Innovations GmbH
      2023   Phase 3   EUCTR2018-003453-16-BE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Advate 1000IU powder and solvent FOR solution FOR injection
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Advate 500 IU powder and solvent FOR solution FOR injection
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   Baxalta Innovations GmbH
      2023   Phase 3   EUCTR2018-003453-16-BE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Alphanate
   Prof Flora Peyvandi, MD
      2012   Phase 3   EUCTR2006-001383-23-GB   Germany;Italy;Spain;United Kingdom
Alphanate SD/HT
   Grifols Biologicals, LLC
      2007   Phase 4   NCT00555555   United States
Alphanate*INF 1F 1000UI+F 10ML
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
Alphanate*INF 1F 1500UI+F 10ML
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
Alphanate*INF 1F 250UI+F 5ML
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
Alphanate*INF 1F 500UI+F 5ML
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
Apcc, apcc + TXA
   Oslo University Hospital
      2011   Phase 4   NCT01800435   Norway
ARC 1779
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
ARC1779
   Archemix Corp.
      2008   Phase 2   NCT00694785   -
      2008   Phase 2   NCT00632242   Austria
   Medical University of Vienna, Dept. of Clinical Pharmacology
      2009   -   EUCTR2008-008532-82-AT   Austria
ARC1779 injection
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
BAX 111
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
BAX111
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Biostate
   CSL Behring
      2010   Phase 3   NCT01224808   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   Phase 3   NCT01213446   Belarus;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
      2009   Phase 2/Phase 3   NCT00941616   Brazil;Bulgaria;Poland;Russian Federation;Ukraine
   CSL Behring GmbH
      2011   -   EUCTR2009-017301-11-DE   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   -   EUCTR2009-017753-34-DE   Belarus;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
      2010   -   EUCTR2009-017301-11-PL   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   -   EUCTR2009-017301-11-BG   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2009   -   EUCTR2008-004922-18-BG   Bulgaria
      -   Phase 3   EUCTR2009-017753-34-BG   Belarus;Bulgaria;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
   CSL Limited
      -   -   EUCTR2014-005401-20-Outside-EU/EEA   Australia
Blood coagulation factor viii and VWF, human
   CSL Behring
      2001   Phase 4   NCT00168090   United States
Blood sample
   University Hospital, Lille
      2023   -   NCT04119908   France
Bortezomib
   Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
      2020   Phase 4   ChiCTR2000035067   China
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03700229   China
BT200
   Medical University of Vienna, Department of Clinical Pharmacology
      2024   Phase 2   EUCTR2023-000044-34-AT   Austria
Catridecacog
   Novo Nordisk A/S
      2010   -   EUCTR2010-020192-23-GB   Austria;Denmark;Finland;France;Germany;Italy;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom
      2010   -   EUCTR2008-007883-41-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   Phase 3   NCT00978380   Austria;Canada;Finland;France;Germany;Israel;Italy;Japan;Spain;Switzerland;United Kingdom;United States
      2009   Phase 3   EUCTR2008-007883-41-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-007883-41-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-ES   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   NCT00713648   Austria;Canada;Finland;France;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States
      2008   Phase 3   EUCTR2006-003148-51-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-003148-51-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2003   Phase 1   NCT00056589   United States
Cluvot
   CSL Behring LLC
      -   -   EUCTR2014-003764-20-Outside-EU/EEA   United States
Coagadex
   Bio Products Laboratory
      2018   -   NCT03161626   United States
   Kedrion S.p.A.
      2025   Phase 3   NCT06963216   -
CoagulacióN factor viii
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom
Coagulation factor viii
   Baxter Innovations GmbH
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
   INSPIRATION BIOPHARMACEUTICALS
      2012   -   EUCTR2011-000181-34-IT   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States
   Octapharma AG
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States
Coagulation factor xiii
   NOVO NORDISK
      2009   -   EUCTR2008-007883-41-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
Cyclophosphamide
   Zhang Lei, MD
      2017   Phase 4   NCT03384277   China
Daratumumab and corticosteroid treatment
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 4   NCT05849740   China
Ddavp
   Rigshospitalet, Copenhagen
      2006   Phase 4   EUCTR2005-004496-38-DK   Denmark
Desmopressin
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
   Groupe Maladies hémorragiques de Bretagne
      2022   -   NCT06020456   France
   Pontificia Universidad Catolica de Chile
      2009   Phase 4   NCT01994330   Chile
   Rigshospitalet, Copenhagen
      2006   Phase 4   EUCTR2005-004496-38-DK   Denmark
Desmopressin acetate
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
   Centers for Disease Control and Prevention
      2001   -   NCT00111215   United States
Desmopressine
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands
Efanesoctocog alfa
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
   Bioverativ, a Sanofi company
      2021   Phase 1   NCT04770935   France;United States
   Sanofi
      2025   Phase 4   NCT06941870   -
   Sanofi K.K.
      2020   Phase 3   JPRN-jRCT2080225103   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Republic of Korea;Spain;Taiwan;United Kingdom;United States
Emicizumab
   Bleeding and Clotting Disorders Institute Peoria, Illinois
      2022   Phase 1   NCT05500807   United States
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225056   Japan
   Hoffmann-La Roche
      2020   Phase 3   NCT04158648   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;South Africa;Spain;United Kingdom;United States
   Indiana Hemophilia &Thrombosis Center, Inc.
      2022   Phase 4   NCT04567511   United States
   University of Washington
      2022   Phase 2   NCT05345197   United States
Emicizumab injection
   GWT-TUD GmbH
      2021   Phase 2   NCT04188639   Austria;Germany
Eqwilate
   Octapharma
      2019   -   NCT04106908   France
F13CD
   NOVO NORDISK
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
F8VR
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2010-023666-46-PL   Poland
Factane 200 IU/ML
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2010-023666-46-PL   Poland
Factor viii concentrate
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden
Factor VON willebrand
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany
Factor X
   Bio Products Laboratory
      2015   Phase 3   NCT01721681   United Kingdom
      2011   Phase 3   NCT01086852   Germany;Spain;Turkey;United Kingdom;United States
Factor xiii
   CSL Behring LLC
      -   -   EUCTR2014-003764-20-Outside-EU/EEA   United States
Factor xiii concentrate (human), pasteurized
   CSL Behring LLC
      2009   -   EUCTR2009-010722-19-ES   Spain
      2009   Phase 2   EUCTR2009-010387-41-ES   Spain
Fanhdi
   Instituto Grifols S.A.
      2013   Phase 4   EUCTR2012-003450-92-ES   Spain
Fanhdi 100 UI
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
Fanhdi 100 UI fviii-120 UI FVW
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom
Fanhdi 25 UI
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
Fanhdi 25 UI fviii-30 UI FVW
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom
Fanhdi 250UI*1F 250UI+F 10ML
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
Fanhdi 50 UI
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
Fanhdi 50 UI fviii-60 UI FVW
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom
Fanhdi*INF FL 250UI+SIR solv+S
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
Fanhdi*INF FL 500UI+SIR solv+S
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
Fanhdi*INF FL1000UI+SIR solv+S
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
Fanhdi*INF FL250UI+SIR solv+S
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
Fibrinogen plasma concentration, coagulation factor xiii activity
   Masaryk Hospital Krajská zdravotní a.s.
      2018   -   NCT03634215   Czechia
Fibrogammin
   CSL Behring LLC
      -   -   EUCTR2014-003764-20-Outside-EU/EEA   United States
   Christian Haslinger
      2024   Phase 4   NCT06481995   Switzerland
Fibrogammin P
   Children's Hospital of Orange County
      2000   -   NCT00640289   United States
Fibrogammin® P
   CSL Behring LLC
      2009   -   EUCTR2009-010722-19-ES   Spain
Fibrogammin®P
   CSL Behring LLC
      2009   Phase 2   EUCTR2009-010387-41-ES   Spain
Haemate P
   Bio Products Laboratory
      2004   Phase 2   NCT02250508   Israel
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
Haemate-P, wilate
   Centre of Thrombosis and Haemostasis
      2007   -   EUCTR2007-004943-31-SE   Sweden
Haemate® P 250
   Octapharma AG
      2008   Phase 2   EUCTR2008-001910-25-SK   Slovakia
Hemofix
   Hadassah Medical Organization
      2016   -   NCT01651468   Israel
Human coagulation factor viii
   Bio Products Laboratory
      2004   Phase 2   NCT02250508   Israel
      2001   Phase 3   NCT02246881   Poland;United Kingdom
      -   Phase 3   EUCTR2006-000664-85-PL   Poland;United Kingdom
      -   Phase 3   EUCTR2006-000663-28-PL   Poland;United Kingdom
   CSL Behring GmbH
      2016   Phase 4   EUCTR2013-003305-25-GR   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   -   EUCTR2013-003305-25-PT   Ireland;Portugal;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-IE   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-GB   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-DE   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-AT   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2011   -   EUCTR2009-017301-11-DE   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   -   EUCTR2009-017753-34-DE   Belarus;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
      2010   -   EUCTR2009-017301-11-PL   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   -   EUCTR2009-017301-11-BG   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2009   -   EUCTR2008-004922-18-BG   Bulgaria
      -   Phase 3   EUCTR2009-017753-34-BG   Belarus;Bulgaria;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
      -   Phase 4   EUCTR2013-003305-25-PL   Austria;Germany;Greece;Ireland;Poland;United Kingdom
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2010-023666-46-PL   Poland
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany
   Prof Flora Peyvandi, MD
      2012   Phase 3   EUCTR2006-001383-23-GB   Germany;Italy;Spain;United Kingdom
Human coagulation factor viii / VON willebrand factor
   CSL Limited
      -   -   EUCTR2014-005401-20-Outside-EU/EEA   Australia
Human coagulation factor viii, VON willebrand factor
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2022   Phase 3   EUCTR2020-004344-28-CZ   Albania;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Germany;Moldova, Republic of;Netherlands;North Macedonia;Russian Federation;Ukraine;United States
      -   Phase 3   EUCTR2020-004344-28-DE   Belarus;Canada;Czech Republic;Germany;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine;United States
Human coagulation factor viii, VON willebrand factor complex
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom
   Octapharma AG
      2020   Phase 3   EUCTR2018-004675-13-HR   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States
      2019   Phase 3   EUCTR2018-004675-13-HU   Belarus;Bulgaria;Croatia;Czech Republic;Hungary;Lebanon;Russian Federation;Ukraine;United States
      -   Phase 3   EUCTR2018-004675-13-BG   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States
Human coagulation factor viii, VON willebrand human coagulation factor
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2022   Phase 3   EUCTR2020-004344-28-CZ   Albania;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Germany;Moldova, Republic of;Netherlands;North Macedonia;Russian Federation;Ukraine;United States
      -   Phase 3   EUCTR2020-004344-28-DE   Belarus;Canada;Czech Republic;Germany;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine;United States
Human coagulation factor X
   Bio Products Laboratory
      2010   Phase 3   NCT00930176   Germany;Spain;Turkey;United Kingdom;United States
   Bio Products Laboratory Limited
      2015   Phase 3   EUCTR2012-003093-98-GB   Turkey;United Kingdom
   Bio Products Laboratory Ltd
      2009   -   EUCTR2009-011145-18-GB   Germany;Spain;Turkey;United Kingdom;United States
Human factor X
   Bio Products Laboratory
      2009   Phase 3   EUCTR2009-011145-18-ES   Germany;Spain;United Kingdom
   Bio Products Laboratory Limited
      2015   Phase 3   EUCTR2012-003093-98-GB   Turkey;United Kingdom
      2012   -   EUCTR2009-015086-31-ES   Germany;India;Spain;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015086-31-GB   Germany;India;Spain;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-011145-18-DE   Germany;Spain;United Kingdom
   Bio Products Laboratory Ltd
      2009   -   EUCTR2009-011145-18-GB   Germany;Spain;Turkey;United Kingdom;United States
Human VON willebrand factor
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   CSL Behring GmbH
      2016   Phase 4   EUCTR2013-003305-25-GR   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   -   EUCTR2013-003305-25-PT   Ireland;Portugal;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-IE   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-GB   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-DE   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-AT   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2011   -   EUCTR2009-017301-11-DE   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   -   EUCTR2009-017753-34-DE   Belarus;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
      2010   -   EUCTR2009-017301-11-PL   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      2010   -   EUCTR2009-017301-11-BG   Bulgaria;Germany;Poland;Russian Federation;Ukraine
      -   Phase 4   EUCTR2013-003305-25-PL   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      -   Phase 3   EUCTR2009-017753-34-BG   Belarus;Bulgaria;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom
   LFB BIOTECHNOLOGIES
      2010   Phase 3   EUCTR2007-004116-32-BE   Belgium;France
      2008   Phase 3   EUCTR2007-004116-32-FR   Belgium;France
      2005   Phase 4   EUCTR2005-001746-17-BE   Belgium
      2005   -   EUCTR2004-005051-34-BE   Belgium
      -   Phase 4   EUCTR2005-001746-17-PL   Belgium;Poland
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States
   Octapharma AG
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States
   Prof Flora Peyvandi, MD
      2012   Phase 3   EUCTR2006-001383-23-GB   Germany;Italy;Spain;United Kingdom
Human VWF/fviii concentrate
   Octapharma
      2011   Phase 3   NCT01365546   Bulgaria;India;Italy;Oman;Poland;Romania;South Africa;Turkey;United States
Humate-P
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden
Hydrogen
   Medical University of Vienna, Department of Clinical Pharmacology
      2024   Phase 2   EUCTR2023-000044-34-AT   Austria
Lyophilized concentrate OF human coagulation VON willebrand factor and factor viii
   Unity Health Toronto
      2024   Phase 3   NCT06205095   Canada
Marketed plasma-derived VWF/fviii concentrate
   Baxalta now part of Shire
      2008   Phase 1   NCT00816660   Austria;Canada;Germany;Italy;United Kingdom;United States
Minirin
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
Minrin
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
Natriumchlorid
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
NN 1841
   Novo Nordisk A/S
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom
NN1841
   Novo Nordisk A/S
      2010   -   EUCTR2010-020192-23-GB   Austria;Denmark;Finland;France;Germany;Italy;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom
      2010   -   EUCTR2008-007883-41-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-007883-41-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-007883-41-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-ES   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-003148-51-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-003148-51-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
OBI-1
   Baxalta now part of Shire
      2014   -   NCT01968655   United States
      2010   Phase 2/Phase 3   NCT01178294   Canada;France;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2012   -   EUCTR2011-000181-34-SE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-HU   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-DE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
   INSPIRATION BIOPHARMACEUTICALS
      2012   -   EUCTR2011-000181-34-IT   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
Obizur
   Baxalta now part of Shire
      2015   -   NCT02610127   United States
   Takeda
      2025   -   NCT06550882   -
Obyoctocog alfa
   Baxter Innovations GmbH
      2012   -   EUCTR2011-000181-34-SE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-HU   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-000181-34-DE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States
Octanate 100 UI/ML, poudre ET solvant pour solution injectable
   OCTAPHARMA AG
      2007   -   EUCTR2005-004435-22-FR   Czech Republic;France
Octanate 50 UI/ML, poudre ET solvant pour solution injectable
   OCTAPHARMA AG
      2007   -   EUCTR2005-004435-22-FR   Czech Republic;France
Octocog alfa
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxalta Innovations GmbH
      2023   Phase 3   EUCTR2018-003453-16-BE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
   Spanish Society of Thrombosis and Haemostasis
      2016   -   NCT03006965   Spain
   St. James' Hospital
      2013   -   EUCTR2013-003240-23-IE   Ireland
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2023   Phase 3   EUCTR2020-003304-13-IT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
   Takeda Development Center Americas, Inc.
      2024   Phase 3   EUCTR2020-003304-13-NL   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-NO   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-FR   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-ES   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-AT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-SE   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-IE   Austria;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
Octostim
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
   Rigshospitalet, Copenhagen
      2006   Phase 4   EUCTR2005-004496-38-DK   Denmark
Oprelvekin, interleukin 11, IL-11
   Margaret Ragni
      2008   Phase 2   NCT00524342   United States
      2008   Phase 2   NCT00524225   United States
   University of Pittsburgh
      2010   Phase 2   NCT00994929   United States
Optivate
   Bio Products Laboratory
      2007   Phase 3   NCT00404300   Israel;United Kingdom
      2006   Phase 3   NCT00387192   Israel;United Kingdom
      2006   Phase 3   EUCTR2006-000664-85-GB   Poland;United Kingdom
      2006   Phase 3   EUCTR2006-000663-28-GB   Poland;United Kingdom
      2004   Phase 2   NCT02250508   Israel
      2001   Phase 3   NCT02246881   Poland;United Kingdom
      -   Phase 3   EUCTR2006-000663-28-PL   Poland;United Kingdom
Phosphate
   Medical University of Vienna, Department of Clinical Pharmacology
      2024   Phase 2   EUCTR2023-000044-34-AT   Austria
Physiologische kochsalzlösung fresenius - infusionslösung
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Phytomenadione
   Region Skane
      2019   -   NCT03782025   Sweden
Plasma-derived fviii/VWF concentrate
   Grifols Therapeutics LLC
      2013   Phase 4   NCT02472665   Spain
Prednisone
   Georgetown University
      2006   Phase 2/Phase 3   NCT00306670   United States
Prothrombin complex concentrate
   CSL Behring
      2005   Phase 3   NCT00168077   Austria;Germany;Hungary;Israel;Lithuania;Netherlands;Poland;Switzerland
Rahf
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxter Innovations GmbH
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Recombinant activated factor VII
   Hoffmann-La Roche
      2025   -   NCT06883240   Belgium;Colombia;Italy;Japan;Spain;United Kingdom
Recombinant coagulation fviii FC – VON willebrand factor – xten fusion protein
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
   Bioverativ Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002023-15-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
Recombinant coagulation fviii FC –VON willebrand factor – xten fusion protein
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
Recombinant factor xiii
   NOVO NORDISK
      2009   -   EUCTR2008-007883-41-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
   Novo Nordisk A/S
      2010   -   EUCTR2010-020192-23-GB   Austria;Denmark;Finland;France;Germany;Italy;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom
      2010   -   EUCTR2008-007883-41-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-007883-41-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-007883-41-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-ES   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-007883-41-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-003148-51-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-003148-51-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2006-003148-51-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom
Recombinant human coagulation factor viii FC - VON willebrand facto
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
Recombinant human coagulation factor viii FC - VON willebrand factor - xten fusion protein
   Bioverativ Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002023-15-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
Recombinant human coagulation factor viii FC - VON willebrand factor -xten fusion protein
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States
Recombinant human VON willebrand factor
   Baxalta Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Recombinant interleukin-11
   University of Pittsburgh
      2004   Phase 2   NCT00151125   United States
Recombinant VON willebrand factor
   Baxalta Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Baxalta now part of Shire
      2015   Phase 3   NCT02283268   Australia;Austria;Czech Republic;Czechia;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   NCT01410227   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2008   Phase 1   NCT00816660   Austria;Canada;Germany;Italy;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Margaret Ragni
      2019   Phase 3   NCT02606045   United States
   Nicoletta C Machin
      2021   Phase 3   NCT04344860   United States
Recombinant VON willebrand factor 1300IU
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Recombinant VON willebrand factor 650IU
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Recomibnant human VON willebrand factor
   Baxalta Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Rfviia, rfviia + TXA
   Oslo University Hospital
      2011   Phase 4   NCT01800435   Norway
Rfviii
   Baxalta now part of Shire
      2019   Phase 3   NCT03879135   Austria;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United States
      2011   Phase 3   NCT01410227   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2008   Phase 1   NCT00816660   Austria;Canada;Germany;Italy;United Kingdom;United States
Rituxan
   Georgetown University
      2006   Phase 2/Phase 3   NCT00306670   United States
Rituximab
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03700229   China
   Zhang Lei, MD
      2017   Phase 4   NCT03384277   China
RO5534262 emicizumab
   GWT-TUD GmbH
      2021   Phase 2   EUCTR2019-004430-42-DE   Austria;Germany
      2021   Phase 2   EUCTR2019-004430-42-AT   Austria;Germany
Rondoraptivon pegol
   Medical University of Vienna, Department of Clinical Pharmacology
      2024   Phase 2   EUCTR2023-000044-34-AT   Austria
Rurioctocog alfa pegol
   Spanish Society of Thrombosis and Haemostasis
      2016   -   NCT03006965   Spain
Rvwf
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxalta now part of Shire
      2019   Phase 3   NCT03879135   Austria;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United States
      2015   Phase 3   NCT02283268   Australia;Austria;Czech Republic;Czechia;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   NCT01410227   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2008   Phase 1   NCT00816660   Austria;Canada;Germany;Italy;United Kingdom;United States
   Baxter Innovations GmbH
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Saline solution
   Tirol Kiniken GmbH
      2018   Phase 2   NCT03613584   Austria
Simvastatin
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands
Simvastatine
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands
Sodium chloride
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Standard OF care FOR haemophilia A
   Hoffmann-La Roche
      2020   -   NCT04165135   Italy
Standard OF care fviii replacement therapy
   Spark Therapeutics
      2019   -   NCT03876301   Australia;Canada;Thailand;United States
Steroid
   Zhang Lei, MD
      2017   Phase 4   NCT03384277   China
Sublingual videomicroscopy
   University Hospital, Lille
      2023   -   NCT04119908   France
Susoctocog alfa
   Takeda
      2024   -   NCT06461533   Japan
TAK-577
   Takeda
      2024   -   NCT06173024   -
TAK-672
   Takeda
      2021   Phase 2/Phase 3   NCT04580407   Japan
Tranexamic acid
   Centers for Disease Control and Prevention
      2001   -   NCT00111215   United States
   Margaret Ragni
      2019   Phase 3   NCT02606045   United States
   Nicoletta C Machin
      2021   Phase 3   NCT04344860   United States
   University of Washington
      2019   -   NCT04146376   United States
USE OF A postpartum diary and additional blood draws
   University of Washington
      2019   -   NCT04146376   United States
Veyondi 650IU powder and solvent FOR solution FOR injection
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Veyvondi
   Baxalta Innovations GmbH
      -   Phase 3   EUCTR2016-001477-33-Outside-EU/EEA   Russian Federation;Turkey;Ukraine;United States
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
Veyvondi 1300 IU powder and solvent FOR solution FOR injection
   Baxalta Innovations GmbH
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Veyvondi 1300I IU powder and solvent FOR solution FOR injection
   Baxalta Innovations GmbH
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Veyvondi 1300IU
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2023   Phase 3   EUCTR2020-003304-13-IT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
Veyvondi 1300IU powder and solvent FOR solution FOR injection
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   Baxalta Innovations GmbH
      2023   Phase 3   EUCTR2018-003453-16-BE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
   Takeda Development Center Americas, Inc.
      2024   Phase 3   EUCTR2020-003304-13-NL   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-NO   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-FR   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-ES   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-AT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-SE   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-IE   Austria;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
Veyvondi 650IU
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2023   Phase 3   EUCTR2020-003304-13-IT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
Veyvondi 650IU powder and solvent FOR solution FOR injection
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   Baxalta Innovations GmbH
      2023   Phase 3   EUCTR2018-003453-16-BE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
   Takeda Development Center Americas, Inc.
      2024   Phase 3   EUCTR2020-003304-13-NL   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-NO   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-FR   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-ES   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-AT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-SE   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-IE   Austria;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
VGA039
   Vega Therapeutics, Inc
      2023   Phase 1/Phase 2   NCT05776069   Australia;Austria;Brazil;Canada;India;South Africa;United Kingdom;United States
VON willebrand factor
   Bio Products Laboratory
      -   Phase 3   EUCTR2006-000664-85-PL   Poland;United Kingdom
      -   Phase 3   EUCTR2006-000663-28-PL   Poland;United Kingdom
   CSL Behring GmbH
      2009   -   EUCTR2008-004922-18-BG   Bulgaria
   Fondazione Angelo Bianchi Bonomi
      2012   -   NCT02460458   Finland;France;Germany;Hungary;Iran, Islamic Republic of;Italy;Netherlands;Spain;Sweden;United Kingdom
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   National Center for Research Resources (NCRR)
      1993   Phase 1   NCT00004667   -
   Takeda
      2017   Phase 3   NCT02973087   Canada;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United States
   Tirol Kiniken GmbH
      2018   Phase 2   NCT03613584   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
VON willebrand factor and coagulation factor viii IN combination
   Octapharma AG
      2008   Phase 2   EUCTR2008-001910-25-SK   Slovakia
VON willebrand factor antigen
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden
VON willebrand factor concentrates and factor viii concentrates
   Hoffmann-La Roche
      2025   -   NCT06883240   Belgium;Colombia;Italy;Japan;Spain;United Kingdom
VON willebrand factor ristocetin cofactor
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden
VON willebrand faktor
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Voncento
   CSL Behring
      2015   -   NCT04657887   France
      2015   Phase 4   NCT02552576   Austria;Germany;Greece;Ireland;Poland;United Kingdom
   CSL Behring GmbH
      2016   Phase 4   EUCTR2013-003305-25-GR   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   -   EUCTR2013-003305-25-PT   Ireland;Portugal;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-IE   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-GB   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-DE   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      2015   Phase 4   EUCTR2013-003305-25-AT   Austria;Germany;Greece;Ireland;Poland;United Kingdom
      -   Phase 4   EUCTR2013-003305-25-PL   Austria;Germany;Greece;Ireland;Poland;United Kingdom
   CSL Limited
      -   -   EUCTR2014-005401-20-Outside-EU/EEA   Australia
Vonicog alfa
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxalta Innovations GmbH
      2023   Phase 3   EUCTR2018-003453-16-BE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Baxalta now part of Shire
      2017   Phase 3   NCT02932618   Austria;Belgium;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2023   Phase 3   EUCTR2020-003304-13-IT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
   Takeda
      2024   Phase 3   NCT05582993   France;Ireland;Italy;Japan;United States
   Takeda Development Center Americas, Inc.
      2024   Phase 3   EUCTR2020-003304-13-NL   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-NO   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-FR   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-ES   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      2023   Phase 3   EUCTR2020-003304-13-AT   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-SE   Austria;Canada;China;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
      -   Phase 3   EUCTR2020-003304-13-IE   Austria;France;Ireland;Italy;Japan;Netherlands;Norway;Spain;Sweden;United States
VWD factor viii concentrate
   Centre of Thrombosis and Haemostasis
      2007   -   EUCTR2007-004943-31-SE   Sweden
VWF gene analysis
   Spanish Society of Thrombosis and Haemostasis
      2017   -   NCT02869074   Spain
VWF replacement therapy with wilate
   University of Washington
      2019   -   NCT04146376   United States
VWF SD-35-DH
   LFB BIOTECHNOLOGIES
      2005   Phase 4   EUCTR2005-001746-17-BE   Belgium
      2005   -   EUCTR2004-005051-34-BE   Belgium
      -   Phase 4   EUCTR2005-001746-17-PL   Belgium;Poland
VWF-containing products
   Octapharma
      2019   -   NCT04053699   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Moldova, Republic of;Russian Federation;Ukraine;United States
VWF/fviii products
   Skane University Hospital
      2007   -   NCT00557908   Sweden;United States
Wilate
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
   Octapharma
      2021   Phase 3   NCT04953884   Belarus;Czechia;Germany;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine;United States
   Octapharma AG
      2008   Phase 4   EUCTR2008-000795-24-SE   Sweden
      2007   -   EUCTR2005-001426-84-CZ   Czech Republic;France;Germany
      2006   -   EUCTR2006-002857-54-DE   Germany
      2006   -   EUCTR2005-001426-84-DE   Czech Republic;France;Germany
Wilate 1000
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States
   Octapharma AG
      2020   Phase 3   EUCTR2018-004675-13-HR   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States
      2019   Phase 3   EUCTR2018-004675-13-HU   Belarus;Bulgaria;Croatia;Czech Republic;Hungary;Lebanon;Russian Federation;Ukraine;United States
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States
      -   Phase 3   EUCTR2018-004675-13-BG   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2022   Phase 3   EUCTR2020-004344-28-CZ   Albania;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Germany;Moldova, Republic of;Netherlands;North Macedonia;Russian Federation;Ukraine;United States
      -   Phase 3   EUCTR2020-004344-28-DE   Belarus;Canada;Czech Republic;Germany;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine;United States
Wilate 450
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany
Wilate 500
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States
   Octapharma AG
      2020   Phase 3   EUCTR2018-004675-13-HR   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States
      2019   Phase 3   EUCTR2018-004675-13-HU   Belarus;Bulgaria;Croatia;Czech Republic;Hungary;Lebanon;Russian Federation;Ukraine;United States
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States
      -   Phase 3   EUCTR2018-004675-13-BG   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2022   Phase 3   EUCTR2020-004344-28-CZ   Albania;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Germany;Moldova, Republic of;Netherlands;North Macedonia;Russian Federation;Ukraine;United States
      -   Phase 3   EUCTR2020-004344-28-DE   Belarus;Canada;Czech Republic;Germany;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine;United States
Wilate 900
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany
Wilate® 450
   Octapharma AG
      2008   Phase 2   EUCTR2008-001910-25-SK   Slovakia
Wilfactin
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands
   LFB BIOTECHNOLOGIES
      2010   Phase 3   EUCTR2007-004116-32-BE   Belgium;France
      2008   Phase 3   EUCTR2007-004116-32-FR   Belgium;France
      2005   Phase 4   EUCTR2005-001746-17-BE   Belgium
      2005   -   EUCTR2004-005051-34-BE   Belgium
      -   Phase 4   EUCTR2005-001746-17-PL   Belgium;Poland
Willfact
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria
Wiloctin
   Octapharma AG
      2006   -   EUCTR2006-002857-54-DE   Germany